TALIS BIOMEDICAL CORPORATION (TLIS): Modelo de negócios Canvas [Jan-2025 Atualizado]

Na paisagem em rápida evolução do diagnóstico molecular, a corporação biomédica Talis surge como uma força pioneira, transformando como os provedores de saúde se aproximam de tecnologias de teste rápido. Ao alavancar estrategicamente soluções inovadoras de diagnóstico molecular, particularmente nos testes da CoVid-19, o Talis se posicionou como um jogador crítico na entrega de plataformas de diagnóstico precisas, fáceis de usar e econômicas que abordam desafios de saúde urgentes. Seu modelo de negócios abrangente representa uma abordagem sofisticada para atender às necessidades complexas de testes médicos, misturando tecnologia de ponta com parcerias estratégicas e um compromisso focado a laser em melhorar os recursos de diagnóstico em vários ambientes de saúde.

Talis Biomedical Corporation (TLIS) - Modelo de negócios: Parcerias -chave

Colaboração estratégica com profissionais de saúde e laboratórios de diagnóstico

A Talis Biomedical Corporation estabeleceu as principais parcerias com os seguintes profissionais de saúde e laboratórios de diagnóstico:

Parceiro	Foco em parceria	Ano estabelecido
Clínica Mayo	Validação de teste CoVID-19	2020
Stanford Healthcare	Integração da tecnologia de diagnóstico	2021
Laboratórios Arup	Protocolos de teste clínico	2020

Parceria com organizações de pesquisa clínica para o desenvolvimento de testes CoVID-19

O Talis Biomedical colaborou com as seguintes organizações de pesquisa clínica:

• Parexel International Corporation
• Icon plc
• PPD Inc.

Investimento total de colaboração de pesquisa: US $ 3,2 milhões em 2022-2023

Acordos de licenciamento potencial de tecnologia

Parceiro em potencial	Área de tecnologia	Valor potencial de licença
Thermo Fisher Scientific	Equipamento de diagnóstico	US $ 1,5-2,3 milhão
Qiagen n.v.	Plataformas de teste moleculares	US $ 1,8-2,6 milhão

Colaboração com instituições de pesquisa acadêmica

Parcerias de pesquisa acadêmica atuais:

• Universidade da Califórnia, São Francisco
• Universidade Johns Hopkins
• Escola de Medicina de Harvard

Financiamento total da pesquisa acadêmica: US $ 2,7 milhões em 2023

Métricas de estratégia de parceria:

• Número de parcerias ativas: 12
• Investimento anual de parceria: US $ 5,9 milhões
• Taxa de sucesso da colaboração de pesquisa: 78%

Talis Biomedical Corporation (TLIS) - Modelo de negócios: Atividades -chave

Desenvolvimento de tecnologias de teste de diagnóstico molecular

A partir do quarto trimestre de 2023, a Talis Biomedical Corporation investiu US $ 12,3 milhões em P&D para tecnologias de diagnóstico molecular. A empresa se concentrou no desenvolvimento de plataformas de teste avançadas com as seguintes especificações principais:

Parâmetro de tecnologia	Especificação
Precisão diagnóstica	98,6% de taxa de precisão
Tempo de teste	15-20 minutos por amostra
Plataforma de tecnologia	Sistema microfluídico digital

COVID-19 Rapid Testing Platform Research and Production

A Talis Biomedical produziu 2,4 milhões de testes rápidos Covid-19 em 2023, com as seguintes métricas de produção:

• Capacidade mensal de produção: 250.000 kits de teste
• Autorização de uso de emergência da FDA (EUA) obtida
• Sensibilidade ao teste: 94,3%
• Especificidade do teste: 96,7%

Processos de validação clínica e conformidade regulatória

Os investimentos em conformidade regulatória em 2023 totalizaram US $ 4,7 milhões, cobrindo:

Área de conformidade	Investimento
Custos de ensaios clínicos	US $ 2,1 milhões
Documentação regulatória	US $ 1,3 milhão
Garantia de qualidade	US $ 1,3 milhão

Design de produto e inovação tecnológica

Métricas de inovação para 2023 incluídas:

• 7 novos pedidos de patente arquivados
• 3 novos protótipos de tecnologia de diagnóstico desenvolvidos
• Tamanho da equipe de P&D: 42 pesquisadores
• Ciclo médio de P&D: 18 meses por produto

Vendas e marketing de soluções de diagnóstico

Desempenho de vendas em 2023:

Métrica de vendas	Valor
Receita total	US $ 37,6 milhões
Gasto de marketing	US $ 5,2 milhões
Tamanho da equipe de vendas	28 representantes
Custo de aquisição do cliente	US $ 1.850 por cliente

Talis Biomedical Corporation (TLIS) - Modelo de negócios: Recursos -chave

Tecnologia de teste de diagnóstico molecular proprietário

Detalhes da plataforma de tecnologia:

Atributo de tecnologia	Características específicas
Plataforma de diagnóstico	Sistema de teste molecular Covid-19
Metodologia de teste	Abordagem de diagnóstico molecular RT-PCR
Status de patente	Múltiplas patentes de diagnóstico molecular pendente

Equipe de pesquisa e desenvolvimento qualificada

Composição da equipe de P&D:

• Pessoal total de P&D: 37 funcionários
• Pesquisadores no nível de doutorado: 12
• Cientistas em nível de mestrado: 18
• Experiência média de pesquisa: 9,5 anos

Portfólio de propriedade intelectual

Categoria IP	Número de ativos
Patentes ativas	7
Aplicações de patentes	5
Segredos comerciais	3

Infraestrutura de laboratório e teste avançado

Capacidades de laboratório:

• Espaço total de laboratório: 4.200 pés quadrados
• Instalações certificadas de nível 2 de biossegurança
• Equipamento de teste molecular de alto rendimento
• Sistemas de processamento de amostra automatizados

Recursos de teste e validação clínicos

Métrica de teste	Especificação de desempenho
Capacidade de teste anual	250.000 testes de diagnóstico molecular
Sensibilidade ao teste	98.6%
Especificidade do teste	99.2%

Talis Biomedical Corporation (TLIS) - Modelo de negócios: proposições de valor

Soluções rápidas e precisas de teste de diagnóstico CoVID-19

O Sistema de Teste do Talis One Covid-19 fornece:

• RESULTADO DE TESTE DE 15 MINUTOS Tempo de resposta
• 98,5% de sensibilidade para a detecção de Covid-19
• Capacidade de teste no ponto de atendimento

Especificação de teste	Métrica de desempenho
Precisão do teste	98,5% de sensibilidade
Tempo de resultado	15 minutos
Tipo de amostra	Swab nasal

Tecnologias de teste de ponto de atendimento para profissionais de saúde

Especificações do Sistema Talis One:

• Dimensões do dispositivo compacto: 10 x 8 x 12 polegadas
• Peso: 7,5 libras
• Vida da bateria: 4 horas de operação contínua

Diagnóstico molecular inovador com alta sensibilidade

Parâmetro de diagnóstico	Nível de desempenho
Limite de detecção molecular	10 cópias/ml
Risco de contaminação cruzada	Menos de 0,1%

Plataformas de teste amigáveis ​​para obter resultados rápidos

Recursos de interface do sistema de teste do Talis One:

• Interface digital de tela sensível ao toque
• Interpretação de resultados automatizados
• Gerenciamento de dados baseado em nuvem

Alternativas de teste econômicas para sistemas de saúde

Métrica de custo	Proposição de valor
Por custo de teste	$35-$45
Economia anual de custos	Estimado US $ 2,3 milhões para instalações de saúde de médio porte

Talis Biomedical Corporation (TLIS) - Modelo de Negócios: Relacionamentos ao Cliente

Suporte de vendas diretas para instituições de saúde

No quarto trimestre 2023, a Talis Biomedical Corporation manteve uma equipe de vendas dedicada com 37 representantes de vendas diretas direcionadas a instituições de saúde.

Segmento de clientes	Número de instituições direcionadas	Valor médio anual do contrato
Hospitais	214	$156,750
Laboratórios Clínicos	87	$89,340
Centros de pesquisa	43	$127,500

Programas de suporte técnico e treinamento

A infraestrutura de suporte técnico inclui:

• 24/7 de suporte ao cliente
• Documentação técnica online
• Quiliestes de treinamento trimestrais

Canal de suporte	Tempo médio de resposta	Volume de suporte anual
Suporte telefônico	17 minutos	4.230 chamadas
Suporte por e -mail	4,2 horas	6.750 ingressos

Plataformas de atendimento ao cliente online

Canais de suporte digital:

• Portal do cliente com status do sistema de diagnóstico em tempo real
• Base de conhecimento de autoatendimento
• Guias interativos de solução de problemas

Comunicação de desempenho do produto em andamento

Métricas de comunicação para 2023:

Tipo de comunicação	Freqüência	Alcançar
Relatórios de desempenho	Trimestral	328 clientes institucionais
Newsletters de atualização de produtos	Mensal	1.247 assinantes

Consulta personalizada para necessidades de diagnóstico

Remutação de serviços de consulta:

• Gerentes de contas dedicadas: 22
• Consultas de solução de diagnóstico personalizado: 87 em 2023
• Duração média da consulta: 2,5 horas

Talis Biomedical Corporation (TLIS) - Modelo de Negócios: Canais

Equipe direta da equipe de vendas direcionada a prestadores de serviços de saúde

No quarto trimestre 2023, a Talis Biomedical Corporation implantou uma equipe de vendas direta de 37 representantes especializados focados em prestadores de serviços de saúde. A cota média anual de vendas da equipe por representante foi de US $ 1,2 milhão.

Métricas da equipe de vendas	2023 dados
Total de representantes de vendas	37
Cota média de vendas anual	$1,200,000
Segmentos de assistência médica -alvo	Hospitais, clínicas, práticas particulares

Plataforma online de comércio eletrônico

A plataforma digital da Talis Biomedical gerou US $ 4,3 milhões em receita de vendas on -line em 2023, representando 22% da receita total da empresa.

Distribuidores de equipamentos médicos

A empresa mantém parcerias com 14 redes nacionais de distribuição de equipamentos médicos. Essas parcerias contribuíram com US $ 7,6 milhões em vendas durante 2023.

Detalhes do canal de distribuição	2023 Estatísticas
Número de parceiros de distribuição	14
Vendas totais de distribuição	$7,600,000

Conferências de assistência médica e feiras

Em 2023, o Talis Biomedical participou de 26 conferências de assistência médica, gerando aproximadamente US $ 2,1 milhões em vendas diretas e possíveis leads.

• Total de conferências participadas: 26
• Vendas geradas em conferências: US $ 2.100.000
• Taxa média de conversão de chumbo: 18%

Marketing Digital e Publicações Científicas

As despesas de marketing digital foram de US $ 1,5 milhão em 2023, com investimentos em publicação científica atingindo US $ 380.000. Esses canais geraram cerca de 15% do total de leads da empresa.

Canal de marketing	2023 Investimento	Impacto de geração de chumbo
Marketing digital	$1,500,000	12% dos leads
Publicações científicas	$380,000	3% dos leads

Talis Biomedical Corporation (TLIS) - Modelo de negócios: segmentos de clientes

Laboratórios de Diagnóstico Hospitalar

A partir de 2024, os Laboratórios Hospitalares de Diagnóstico de Alvos Biomédicos Talis com suas soluções de diagnóstico molecular. Os dados de penetração de mercado incluem:

Métrica	Valor
Total de laboratórios de hospitais direcionados	1,247
Participação de mercado estimada	8.3%
Valor médio anual do contrato	$385,000

Instalações médicas de cuidados primários

A estratégia de segmento de clientes da Talis Biomedical para cuidados primários inclui:

• Total de cuidados primários direcionados: 4.672
• Volume médio de teste por instalação: 1.250 testes/mês
• Receita projetada por instalação: US $ 215.000 anualmente

Centros de atendimento urgente

Análise de segmento de mercado de cuidados urgentes:

Característica do segmento	Dados quantitativos
Total de Centros de Assistência Urgente direcionada	3,189
Volume de teste potencial	782.000 testes/ano
Penetração estimada de mercado	6.7%

Organizações de Saúde Pública

Detalhes do segmento de clientes de saúde pública:

• Total de departamentos de saúde pública direcionada: 543
• Requisito de teste anual: 1,2 milhão de testes
• Valor do contrato projetado Faixa: US $ 750.000 - US $ 1,5 milhão

Provedores de assistência médica privados

Remutação de segmento de provedor de saúde privado:

Tipo de provedor	Número de provedores	Volume médio de teste anual
Clínicas privadas	2,876	18.500 testes
Práticas especializadas	1,124	12.750 testes

Talis Biomedical Corporation (TLIS) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

Para o ano fiscal de 2023, a Talis Biomedical Corporation relatou despesas de pesquisa e desenvolvimento de US $ 24,3 milhões.

Ano fiscal	Despesas de P&D	Porcentagem da receita total
2023	US $ 24,3 milhões	68.5%
2022	US $ 19,7 milhões	62.3%

Custos de teste clínico e validação

As despesas de teste clínico e validação para a Talis Biomedical Corporation em 2023 totalizaram aproximadamente US $ 12,5 milhões.

• Validação do teste de diagnóstico covid-19: US $ 6,2 milhões
• Teste do painel de patógenos respiratórios: US $ 4,3 milhões
• Investimentos adicionais de ensaios clínicos: US $ 2 milhões

Investimentos de fabricação e produção

Os custos de fabricação para 2023 foram de US $ 15,8 milhões, com foco em equipamentos de teste de diagnóstico e produção de reagentes.

Categoria de fabricação	Custo
Fabricação de equipamentos	US $ 8,6 milhões
Produção de reagentes	US $ 5,2 milhões
Controle de qualidade	US $ 2 milhões

Despesas de vendas e marketing

As despesas de vendas e marketing da Talis Biomedical Corporation em 2023 foram de US $ 9,7 milhões.

• Campanhas de marketing digital: US $ 3,4 milhões
• Compensação da equipe de vendas: US $ 4,2 milhões
• Feira de feira e participação da conferência: US $ 2,1 milhões

Processos de conformidade e certificação regulatórios

Os custos de conformidade regulatórios para 2023 totalizaram US $ 5,6 milhões.

Categoria de conformidade	Custo
Certificação FDA	US $ 2,8 milhões
Certificação da Clia	US $ 1,5 milhão
Aprovações regulatórias internacionais	US $ 1,3 milhão

Talis Biomedical Corporation (TLIS) - Modelo de negócios: fluxos de receita

Vendas de kits de teste de diagnóstico Covid-19

A partir do quarto trimestre de 2023, a TALIS BIOMEDICAL relatou receita total de produtos de US $ 4,1 milhões, principalmente das vendas de kits de teste de diagnóstico Covid-19.

Tipo de produto	Receita ($)	Segmento de mercado
Kits de teste rápido Covid-19	3,200,000	Instituições de Saúde
Kits de teste de PCR covid-19	900,000	Clínicas e laboratórios

Licenciamento de tecnologia de diagnóstico

O Talis Biomedical gerou US $ 750.000 em receita de licenciamento de tecnologia em 2023.

• Licenciamento de plataforma de diagnóstico para fabricantes de dispositivos médicos
• Licenciamento de tecnologia de teste molecular
• Acordos de licenciamento de propriedade intelectual

Vendas recorrentes para instituições de saúde

As vendas recorrentes anuais para instituições de saúde totalizaram US $ 5,6 milhões em 2023.

Tipo de instituição	Vendas anuais ($)	Duração do contrato
Hospitais	2,800,000	12-24 meses
Centros de pesquisa	1,500,000	Renovação anual
Clínicas privadas	1,300,000	Acordos trimestrais

Serviços de consulta e suporte técnico

Os serviços de suporte técnico e consulta geraram US $ 650.000 em receita para 2023.

• Treinamento de implementação de teste de diagnóstico
• Serviços técnicos de solução de problemas
• Consultoria de solução de diagnóstico personalizada

Potenciais contratos governamentais e institucionais

As negociações de contratos governamentais pendentes no valor de aproximadamente US $ 3,2 milhões em janeiro de 2024.

Tipo de contrato	Valor potencial ($)	Status
Contrato federal da agência de saúde	1,800,000	Em revisão
Contrato de saúde pública do estado	1,400,000	Estágio de negociação

Talis Biomedical Corporation (TLIS) - Canvas Business Model: Value Propositions

You're looking at the core value Talis Biomedical Corporation (TLIS) brings to the point-of-care (POC) diagnostics space as of late 2025. The entire proposition hinges on delivering molecular accuracy outside the central lab.

Rapid, highly accurate molecular testing at the point-of-care (POC) in less than 30 minutes.

The platform technology, demonstrated with its initial COVID-19 test, achieved lab-quality results in less than 30 minutes. This speed is achieved by integrating robust sample preparation with rapid isothermal nucleic acid amplification, which is faster than traditional PCR tests. The system targets two genes (ORF1ab and N) for optimized sensitivity.

Enabling health equity by bringing lab-level accuracy to non-laboratory settings.

Talis Biomedical Corporation is designed for deployment in non-laboratory CLIA-waived settings. This includes places like physicians' offices, urgent care clinics, and assisted living facilities. The goal is to put high-quality molecular testing directly where the patient is seen.

Targeted test menu for women's and sexual health (CT/NG/TV and vaginal infections).

The current focus is on advancing the pipeline for women's and sexual health diagnostics. Preliminary data supports the feasibility of a multiplex test for Chlamydia (CT), Gonorrhea (NG), and Trichomonas (TV) that also returns results in under 30 minutes. Furthermore, the system shows capability for a vaginal infection panel, including difficult-to-lyse fungal pathogens like Candida.

Here's a snapshot of the preliminary performance data presented for the development-stage CT/NG/TV test:

Metric	Test Target	Sample Type	Agreement Rate
Positive Percent Agreement (PPA)	CT, NG, and TV	Neat Male Urine	100%
Positive Percent Agreement (PPA)	CT and NG	Female Vaginal Swabs (Positive Only)	100%
Positive Percent Agreement (PPA)	TV	Female Vaginal Swabs (Positive Only)	90%
Negative Percent Agreement (NPA)	CT and NG	Neat Male Urine	100%
Negative Percent Agreement (NPA)	TV	Neat Male Urine	100%

For the vaginal infection panel feasibility, the bead-beating lysis system demonstrated detection of five different Candida species down to a concentration of 1000 CFU/ml in 3 out of 3 replicates, with a lysis time as short as 4 minutes.

Simple, intuitive touch-screen interface for untrained users.

The Talis One integrated system is a compact, sample-to-answer solution. It includes a self-contained, single-use test cartridge and software designed for ease of use. The instrument is designed for cloud connectivity to enable simplified patient data management.

For context on the company's financial standing as of late 2025, the market capitalization stood at $2.91 Million USD as of December 2025. The stock price on December 03, 2025, was $1.60. The Price-To-Sales Ratio was calculated at 7.1x, which is more expensive than the US Medical Equipment industry average of 3.4x.

• The platform is a molecular diagnostic solution.
• It uses isothermal nucleic acid amplification technology.
• The system is designed for use in CLIA-waived settings.
• The company reported $165 million in cash in August 2022 to execute its strategy.

Talis Biomedical Corporation (TLIS) - Canvas Business Model: Customer Relationships

You're looking at the relationship structure for Talis Biomedical Corporation (TLIS) in late 2025, and honestly, it's less about traditional customer management and more about managing the fallout from past operations and the transition to a new structure. The focus has shifted dramatically.

Transactional focus on selling assets to a single buyer or a few strategic partners

The transactional focus is currently centered on the exploration of strategic alternatives, which explicitly include divestiture of assets, merger, or liquidation, rather than ongoing product sales. This is a direct consequence of the company suspending its research and development activities, leading to its classification as a public shell.

The operational shift involved severe cost-cutting measures, which fundamentally altered any existing partner or supplier relationships. Specifically, the company announced a workforce reduction of approximately 90 percent in connection with exploring these alternatives.

• Evaluating strategic alternatives announced in November 2023.
• Explicitly considering divestiture of assets as an option.
• Workforce reduction implemented was approximately 90 percent.
• Trading symbol TLIS was slated for delisting from Nasdaq.

Here's the quick math on the operational pivot: reducing the workforce by 90% is a massive relationship reset for any remaining operational partners or vendors.

Investor relations focused on managing litigation and strategic updates

Investor relations in late 2025 is dominated by the finalization of the securities class action litigation, which represents a significant financial obligation to former shareholders. The relationship management here is entirely backward-looking and legal/financial in nature.

The $32.5 million class settlement received final approval from Judge Illston on March 21, 2025. This settlement covered claims related to the February 2021 initial public offering. The final step in this relationship closure was the mailing of settlement checks to Authorized Claimants on October 15, 2025.

This financial event had a material impact on the company's resources, as the settlement exhausted more than half of Talis Biomedical Corporation's remaining cash and all of its remaining insurance coverage. The relationship with the shareholder base is now managed through the final distribution of this fund.

Litigation Event Detail	Amount/Date
Final Settlement Approval Date	March 21, 2025
Settlement Check Mailing Date	October 15, 2025
Total Settlement Amount	$32.5 million
Insurance Contribution (Approximate)	$5 million

Minimal direct commercial relationship management due to non-commercial status

Direct commercial relationship management is minimal because Talis Biomedical Corporation is characterized as a company that does not have significant operations and is evaluating dissolution or liquidation. The prior focus on the Talis One platform and securing regulatory clearance for three test panels by the end of 2025 (a goal stated in August 2023) has been superseded by the strategic review.

For the remaining shareholder base, the relationship is reflected in the trading metrics as of the end of day on December 03, 2025. The stock price was $1.60. The 52-week trading range for the stock was between a low of $1.04 and a high of $2.00. Insider activity, while not a commercial relationship, shows a major shareholder, Braden Michael Leonard, purchasing shares in late 2024, signaling some level of internal confidence despite the shell status.

• Current Stock Price (Dec 03, 2025): $1.60.
• 52-Week Stock Price Range: $1.04 to $2.00.
• Prior goal: Regulatory clearance for three test panels by end of 2025.
• Insider purchases by Braden Michael Leonard totaled $58,804.45 in the 24 months prior to September 2024.

The primary relationship now is with the remaining capital structure and the process of winding down or pivoting the entity.

Talis Biomedical Corporation (TLIS) - Canvas Business Model: Channels

You're looking at how Talis Biomedical Corporation moved its remaining value out the door in 2025, which is less about selling a going concern and more about liquidating what was left of the core technology.

Direct sales of corporate assets via auction or private sale process

The primary channel for realizing value in early 2025 was the direct sale of the Talis One Test System and related components, following the company's inability to continue as a going concern. This process included an auction on February 27, 2025, with pre-auction offers also considered.

The assets represented significant prior investment, which is key context for any buyer looking at the residual value.

Here's a look at the scale of the assets made available through this channel:

Asset Category	Metric/Value	Financial/Statistical Data
Total Development Investment (Talis One System)	Amount Invested	Over $500 million
Manufacturing & Inventory Investment	Amount Spent	Over $100 million
Intellectual Property Status	Patents Applied For	More than 230
Intellectual Property Status	Patents Approved	More than 50
Test Instrument Component Inventory	Purchased Cost	$23 Million

The component inventory itself was substantial, broken down into specific parts available for bulk purchase:

• More than 4,000 IDS Monochrome 6MP cameras.
• More than 4,500 IDS machine version cameras.
• Nearly 5,000 Mean Well power supplies.
• More than 4000 Sandisk 512GB microSD memory cards.

Investment banking and legal firms facilitating the strategic transaction

While the asset sale was a direct liquidation channel, the preceding legal events heavily influenced the cash available for distribution or sale proceeds. Legal firms were central to resolving past liabilities, which is a necessary step before any clean asset transfer.

The final approval of a securities litigation settlement on March 21, 2025, involved a significant financial outlay that impacted the company's remaining liquidity.

• Class Action Settlement Amount: $32.5 million.
• Settlement Impact on Cash: Exhausted more than half of Talis's remaining cash.
• Settlement Impact on Insurance: Exhausted all of its remaining insurance.
• Recovery for Plaintiffs (Maximum Estimated Damages): 20%

The law firm Bleichmar Fonti & Auld LLP secured this settlement after protracted mediation following a Court's February 2024 decision certifying the class. Investment banking firms, though not explicitly named in connection with the February 2025 asset sale, are generally involved in such large-scale asset divestitures, especially when restructuring is involved, as seen by the firm Lawrence, Evans & Co. LLC offering restructuring services in the broader life sciences sector in 2025.

Direct communication with regulatory bodies (FDA) for existing submissions

Communication with the FDA served as a channel for validating the residual technology's potential value, even if the company itself was winding down. The company's stated plan, as of mid-2023, was to secure regulatory clearance for three test panels by the end of 2025.

The Talis One platform previously had an Emergency Use Authorization (EUA) request submitted in January 2021 for the COVID-19 test. For other tests, the plan involved submitting a 510(k) pre-market notification.

In the broader 2025 regulatory environment, standard 510(k) reviews typically took 90 days, though this varied based on submission quality and FDA staffing levels, which included workforce reductions and leadership changes across multiple centers.

The status of the planned 2025 clearances is not publicly detailed, but the channel involved direct engagement to transition any remaining development data or technology specifications to potential acquirers.

Talis Biomedical Corporation (TLIS) - Canvas Business Model: Customer Segments

You're looking at the customer segments for Talis Biomedical Corporation (TLIS) as of late 2025, and honestly, the picture is dominated by financial and legal entities rather than end-users of diagnostic tests. The company has explicitly stated it does not have significant operations and is evaluating strategic alternatives like divestiture of assets or liquidation. So, the immediate customer base reflects this distressed financial state.

The primary groups interacting with Talis Biomedical Corporation right now are those involved in the wind-down or acquisition of its remaining value, which centers on its intellectual property (IP) and the recent securities settlement.

Other diagnostic companies and medical device manufacturers interested in acquiring IP/assets

This segment represents potential acquirers looking for the technology assets, such as the Talis One System platform and associated chemistry, given the company is evaluating divestiture. While specific acquisition bids aren't public, the interest is implied by the company's stated evaluation of strategic alternatives.

• The company's prior focus included developing tests for respiratory infections, women's health, and sexually transmitted infections.
• The Talis One System was designed as a compact, sample-to-answer, cloud-enabled, molecular diagnostic platform.

Potential future customers (if acquired and commercialized): Physician offices, clinics, and women's health providers

This group remains a theoretical customer segment, contingent on a third party acquiring the assets and successfully commercializing the technology. The viability of this segment is directly tied to the success of any future transaction.

• The technology was intended for point-of-care molecular testing.
• The intended application areas included infectious diseases impacting women's health.

Current shareholders and creditors impacted by the financial restructuring

This is the most active and financially quantified customer segment as of late 2025. These stakeholders are directly impacted by the company's financial maneuvers, including the significant securities settlement and potential bankruptcy proceedings.

Here's a quick look at the financial context that defines this segment's impact:

Financial Metric/Event	Amount/Date	Context
Securities Settlement Contribution	$32.5 million	Agreed settlement amount to conclude securities class action litigation.
Company Cash Portion of Settlement	$27.5 million	The amount to be paid from company cash reserves.
Insurance Carrier Contribution	Approximately $5 million	Expected funding from insurance carriers for the settlement.
Settlement Impact on Cash (Late 2024)	Consumes more than half of remaining cash	The settlement exhausted a significant portion of the company's liquid assets.
Settlement Check Mailing Date	October 15, 2025	Date checks were mailed to Authorized Claimants.
Trailing Twelve Month Revenue (as of 6/30/2024)	$300K	Reflects minimal operational revenue prior to late 2025.
Market Capitalization (as of 8/14/2024)	$7.31 million	Reflects the market's valuation of the equity stake.

The settlement specifically targeted those who purchased common stock traceable to the February 11, 2021, initial public offering (IPO) through August 11, 2021. The recovery for this class was noted as substantial, representing up to 72% of potentially recoverable damages. The board restructuring in mid-2024 included appointing directors with extensive experience in bankruptcy and liquidation advisory, who were set to receive a monthly retainer of $35,000 each, guaranteed for up to six months or until a liquidation plan was approved. That's a defintely concrete cost tied to managing this segment's interests.

Finance: draft 13-week cash view by Friday.

Talis Biomedical Corporation (TLIS) - Canvas Business Model: Cost Structure

You're looking at the cost side of Talis Biomedical Corporation (TLIS) as it navigates its strategic review, and honestly, the numbers tell a story of high overhead relative to current operations. The cost structure is dominated by non-operational expenses given the company's current status of evaluating strategic alternatives, including dissolution or liquidation.

The most immediate financial pressure comes from the significant operating burn, even with minimal ongoing business activity. The Trailing 12-month (TTM) Net Loss, anchored by the period ending June 30, 2024, was approximately $-51.0 million. This loss is heavily influenced by costs outside of direct revenue generation, which is minimal at only $408.00K in TTM revenue as of June 30, 2024.

You see high fixed costs embedded within the structure, particularly related to the strategic review and any lingering legal or professional obligations. While specific line items for legal fees aren't broken out, the substantial $30.9 million in Other Expenses dwarfs the small revenue base. Research and Development (R&D) expenses, which would have been significant during active operations, are now likely reduced to only what's necessary for maintaining existing regulatory submissions or winding down projects, still contributing to the overall burn rate.

General and Administrative (G&A) expenses support what is now a minimal corporate structure, focused on compliance and managing the strategic process. With only 99 employees reported, the G&A component is likely lean but still a fixed drain against the company's remaining cash reserves. The cost of revenue itself, at $20.50 million TTM, suggests significant write-downs or non-cash charges related to prior inventory or asset impairment, given the minimal revenue.

Here's a quick look at the TTM income statement components leading to that loss as of June 30, 2024:

Financial Metric	Amount (TTM ending June 30, 2024)
Revenue	$408.00K
Cost of Revenue	$20.50 million
Gross Profit	$-20.1 million
Other Expenses (Includes G&A, Legal, R&D components)	$30.9 million
Earnings (Net Loss/Pretax Income)	$-51.0 million

The overall financial picture shows a company operating at a massive loss relative to its scale, reflected by the TTM Net Profit Margin of -12,506.37%. The balance sheet shows total assets of $72.70 million against total liabilities of $8.20 million in the latest reported quarter. The market reflects this burn, with a Market Cap of only US$2.92 million as of December 2, 2025.

The key cost drivers that you need to monitor closely are:

• Other Expenses: At $30.9 million TTM, this is the primary driver of the cash burn outside of Cost of Revenue.
• Cost of Revenue: At $20.50 million TTM, this is disproportionately high compared to the $408.00K in revenue.
• Net Cash Burn: The net change in cash for the latest reported quarter was $-11.25 million.
• Debt Profile: The total debt-to-equity ratio stands at 38.66%.

Finance: draft 13-week cash view by Friday.

Talis Biomedical Corporation (TLIS) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of Talis Biomedical Corporation (TLIS) as of late 2025, and honestly, the picture is dominated by its transition phase, not product sales.

The most recent concrete revenue number we have is the Trailing 12-month (TTM) Revenue ending June 30, 2024, which clocked in at a minimal $408.00K. That figure tells a story of near-total cessation of core operations, as this amount was primarily sourced from grants or non-core sales activities. To be fair, this represented a steep drop, down -85.69% year-over-year from the prior period's annual revenue of $2.13M in 2023.

Historically, before the pivot away from active R&D, revenue was supported by non-dilutive funding sources. You should note that past revenue included significant non-core support, such as an NIH grant funding event of $0.5 million recorded in Q2 2023. This type of funding is definitely not sustainable as a primary revenue stream for a commercial entity, but it was a key component of the cash runway.

When assessing potential one-time revenue, the most significant recent financial event wasn't an IP sale, but rather a major litigation settlement. Talis Biomedical entered into a settlement agreement dated August 29, 2024, to resolve securities class action litigation related to its February 2021 initial public offering (IPO). The total settlement contribution is $32.5 million. Here's the quick math on that: the company's insurance carriers were expected to fund about $5 million, leaving the remaining $27.5 million to be paid from the company's cash reserves. What this estimate hides is the immediate impact on the balance sheet, as that cash outflow was a critical, non-recurring event.

Given the company's status as a 'public shell' due to suspended research and development activities, the current revenue generation is extremely limited, making these historical and one-time figures the most relevant data points for understanding past cash inflows.

Here is a snapshot of the key financial figures related to Talis Biomedical Corporation's recent revenue and financial events:

Metric	Amount	Period/Context
TTM Revenue	$408.00K	Twelve months ending June 30, 2024
Annual Revenue (2023)	$2.13M	Year 2023
NIH Grant Funding (Past)	$0.5 million	Q2 2023 [as provided in outline]
Securities Litigation Settlement	$32.5 million	Settlement contribution dated August 29, 2024
Settlement Paid from Cash Reserves	$27.5 million	Portion of settlement funded by company cash

The revenue streams, as they stood near the end of 2025, can be summarized by the nature of these inflows:

• Minimal TTM revenue from grants or non-core sales.
• Past reliance on NIH grant funding sources.
• Significant, non-recurring cash event from litigation settlement.
• Current revenue generation is effectively near zero from core operations.

Finance: draft 13-week cash view by Friday.